Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 November 2023 | Story Prof Matie Hoffman

A decade ago, the former Lamont-Hussey Observatory in Bloemfontein became Southern Africa’s first digital planetarium. Thanks to a collaboration between the University of the Free State (UFS), the Mangaung Metropolitan Municipality, the Department of Science and Innovation, and the Free State Province – as well as donations from trusts, foundations, and businesses – the project has grown and thrived.

Many different shapes, one place

The Naval Hill Planetarium was established in the old Lamont-Hussey Observatory. After the closure of the astronomical observatory, the buildings were refurbished and used by PACOFS as the Observatory Theatre. When the site became available again, it was envisioned to turn it into a planetarium. After many years of hard work, the newly refurbished buildings were opened in 2013 as the Naval Hill Planetarium – the first digital planetarium in Africa south of the Sahara. 

The decade has seen many changes on the site of the former Lamont-Hussey Observatory, founded by the University of Michigan in 1927 to study double stars through the largest refracting telescope in the Southern Hemisphere. Improvements include the conversion of the old telescope building into a modern digital planetarium, the refurbishment of the structure of the old Lamont telescope and its installation as a display outside the old telescope dome, an observing platform, and a new hall for environmental education. The planetarium and the hall are now known as the Centre for Earth and Space, and developments are continuing.

Partners who have supported the project include the American Museum of Natural History (AMNH), the University of Michigan, Old Mutual, Sun International, the Hermann Ohlthaver Trust, ArcelorMittal, the Joan St Leger Lindbergh Charitable Trust, and the CB van Wyk Gesinstrust. In 2022, the Raubex Group and First Technology supported the University of the Free State to upgrade the planetarium’s projection system. Volunteers, including the Friends of the Boyden Observatory and the Naval Hill Planetarium, as well as the Friends of Franklin, have played an invaluable role in supporting and developing this community asset. The planetarium is managed by the Department of Physics at the University of the Free State.

A time to celebrate

During November and December 2023, the planetarium’s first decade will be celebrated with events and special shows, including the South African premier of the AMNH full-dome film, Worlds Beyond Earth. The board of the Southern African Large Telescope (SALT) – the largest single optical telescope in the Southern Hemisphere – will attend the premiere. Many international partners are involved in SALT, and AMNH is one of the shareholders in the SALT Foundation. As part of the partnership between the AMNH and SALT, AMNH provides sponsorship for education and outreach efforts in South Africa. The Naval Hill Planetarium benefits from this initiative and receives content for the planetarium in the form of AMNH full-dome films.

In addition to regular school shows, there will be two public shows every Saturday in November and December – one show in English and one in Afrikaans. In December, there will be additional shows for children. Bookings for shows should be done through Computicket, click here to book. The planetarium can accommodate group bookings and functions (enquiries at +2 51 401 9751 or ficky@ufs.ac.za).

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept